ABSTRACT

According to global cancer report 2019, the burden of cancer will exceed more than 18 million that it became one of the major causes for global mortality rate. There is a pressing need to establish novel drug candidates for cancer treatment. Current work aims to synthesize and evaluate the anti-cancer potential of the novel class of isatin-phenylacetamide derivatives against five different cancer cell lines. A novel series of various substituted isatin-phenylacetamide were synthesized through a feasible scheme. The synthetic scheme involves a multi-step process where the final derivatives (8a-8j and 9a-9j) obtained by the condensation of various substituted isatins intermediates (3a-3j) with the substituted phenyl acetamides (6&7) through imine group. All the synthesized derivatives characterized by IR, 1HNMR and MASS spectral methods and anti-cancer activity evaluated by employing MTT assay for six cancer cell lines and one normal human cell line. All the synthesized compounds were screened for anti-cancer activity against five cancer cell lines including NCI-H1975 (lung), SW48 (colon), HT-3 (cervical), SW626 (ovarian), BT-20 (breast), and one normal human fibroblast cell line (HLF). All the compounds displayed decent cytotoxicity profile when compared with the standard drug doxorubicin. Among the synthesized compounds 9b is the most potent followed by 9i, 9e, 8b, 8f, and 8i against all the cancer cell lines. Comparatively most of the compounds displayed decent cytotoxicity potential relative to the standard drug doxorubicin. Further investigations are needed to establish the detailed mechanism of action of the developed novel isatin-phenylacetamide hybrids. Keywords: Isatin-phenylacetamide, Multistep reaction, Anticancer activity, EGRF-TK
Publication date: 01/04/2022

https://ijbpas.com/pdf/2022/April/MS_IJBPAS_2022_5939.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.4.5939